ASTRO24: 20 Posts Not To Miss From Day 1

The 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO) is ongoing at the Walter E. Washington Convention Center, Washington, DC, from September 29 to October 2, 2024.

The American Society for Radiation Oncology (ASTRO) is a prominent professional organization dedicated to enhancing the field of radiation oncology. Established in 1958, ASTRO’s mission centers on improving patient care through a multifaceted approach that includes education, research, and advocacy.

The meeting is ongoing as a live event with a virtual option available for those unable to attend in person, ensuring broad participation from professionals across the field.

The theme for the 2024 meeting is “Targeting Provider Wellness for Exceptional Patient Care.” This theme emphasizes the importance of mental and physical well-being among healthcare providers, which is crucial for delivering high-quality patient care.

Here are some Highlights from ASTRO24 Day 1:

ASTRO:

“A huge shoutout to our amazing Women Who Curie board members and ASTRO CEO, Laura Thevenot, for their leadership and dedication to ASTRO. Just missing Geraldine Jacobson and Dr. Ng.”

Stephen V Liu:

“Nice setup for posters! Touchscreen allows you browse all posters by disease type. QR code lets you get the poster instantly and lets you navigate figure to figure. Here, predictors of pneumonitis after CRT followed by durvalumab from Jair Bar and team.”

Ajay Aggarwal:

“Excellent talk in presidential plenary at ASTRO24 by Ananya Choudhury about personalising options for radical radiotherapy and improving therapeutic effect for those with muscle invasive bladder cancer.”

Pierre Blanchard:

“Shankar Siva kicks off ASTRO24 presidential session with SBRT for kidney cancer. Excellent talk and superb slides as always. Many important points to use in MTB while deciding btw surgery/RFA/SBRT. Shared decision with patient is key!”

Priyamvada Maitre:

“ASTRO24 Presidential symposium Dr Phuoc Tran explaining scope of radiation in ‘space-time continuum’ of mHSPC

metastasis can ‘back-seed’ or ‘self-seed’,

de novo biology is not same as metachronous,

push to ablate, but be safe.”

Jenna Kocsis:

“Key takeaways from ARRO graduating resident survey:

> 95% got the job type they wanted when they started the process (academic or private)

>90% satisfied with the job they signed

~15% felt job market was tough this year. DOWN from ~70% in 2019-2020.”

Shankar Siva:

“Vedang Murthy continues to raise the Bar(t) with randomised trials in radiotherapy trials. Adjuvant RT in high risk bladder cancer; 8-year accrual, with good safety signal (acute and late tox). Majority of patients had chemotherapy, pN+ve or T3+.”

Aadel Chaudhuri:

“Excited for ASTRO24!! Checkout these abstracts / talks / chaired sessions from Mayo Clinic Radiation Oncology in Rochester— Quite the impressive showing, team!”

Rana McKay:

“Amazing efforts by ⁦Shankar Siva, Chad Tang at ASTRO24 putting RCC in the limelight. ⁦With modern day SABR, RCC is not radio-resistance.⁩”

Rachel Jimenez:

“Thank you VCU Radiation Oncology Residency and Emma Fields for hosting me as a pre-ASTRO24 visiting professor! So impressed by your talents! Special thanks to chief residents Amanda Stark and Joe Wilding, cannot wait to see which department/practice will be lucky enough to hire you!”

Stephen V Liu:

“My first ASTRO talk! Great session with Drs. Alex Louie, Erin Gillaspie, Houda Bahig on the nuances of stage III NSCLC!”

TMC Radiation Oncology:

“Dr. Murthy stole the show at ASTRO2024 while raising the BAR(T)! Vedang Murthy presenting results of the multicentric phase III bladder adjuvant RT (BART) trial ASTRO 2024 with a punch of brilliance and flair! And what’s more, with a simultaneous publication in IJROBP!

Shankar Siva:

“Brandon Mahal presents at the Presidential symposium ASTRO24 discussing practical aspects of boosting the DIL in prostate cancer radiotherapy. Tumour definition on MRI and PET matters! Constraining for the urethra should also be considered.”

Stuart Burri:

“77.8% PFS at 6 months impressive for 177Lu-Dotatate for recurrent grade II or III meningioma. Potentially exciting new option for difficult to manage patients.”

Dasha Klebaner:

“Dr Sandler discusses work life integration among different specialties – radiation oncology among the best! However, physician burnout still higher than general population.”

Shearwood McClelland III:

“Once again grateful to the Radiation Oncology Institute for recognizing our Navigator-Assisted Hypofractionation (NAVAH) program expansion to help Hispanic Breast Cancer patients with 1 of the 4 innovation grants awarded nationally this year!”

Aadel Chaudhuri:

“We have 4 presentations ASTRO24 from our lab this year. Please swing by if you’re free!

Two talks tomorrow (from me) Another 2 on Tuesday — Talk + Poster (from my lead scientist Pradeep Chauhan).”

Ben Slotman:

“Great talk by Vedang Murthy on bladder adjacent radiotherapy at ASTRO24 showing low toxicity rates. Conclusion: No need to be afraid!”

Priyamvada Maitre:

“ASTRO24 Presidential symposium. Gopa Iyer showing exciting times ahead with IO-RT combos in bladder cancer:

Pembro (KEYNOTE-992), Atezo (SWOG NRG S1806) with radiotherapy, ph3 RCT data awaited

EV safety trials

ctDNA etc biomarkers to optimise Bladder Preservation.”

Tyler Seibert:

“We have a problem.

Ananya Choudhury points out many patients with Bladder Cancer are not given optimal treatment. We can do better. Bladder preservation = excellent option.

Adaptive RT for Bladder Cancer: do we know how much it reduces toxicity if treating with empty bladder?”

More posts featuring ASTRO24 on oncodaily.com